Intervention

Dutasteride

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15

Recruiting0

Common conditions7

Lead sponsors shown12

Clinical trials

15 shown

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)NCT05705700 · 2023-02-01

WITHDRAWN

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyNCT02159690 · 2014-09-01

WITHDRAWN

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate CancerNCT01547299 · 2012-03-31

COMPLETED

Validation of Digital Morphometry for Cancer Risk in Benign Prostate BiopsiesNCT01594502 · 2011-09-01

COMPLETED

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerNCT01393730 · 2011-09-01

COMPLETED

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate CancerNCT01342367 · 2010-12-17

ACTIVE_NOT_RECRUITING

Response of Patients on Surveillance for Prostate Cancer to DutasterideNCT01525914 · 2010-05-01

COMPLETED

Economic Analyses of the REDUCE TrialNCT01337258 · 2010-01-01

COMPLETED

Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate CancerNCT00985738 · 2009-09-01

TERMINATED

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate CancerNCT00668642 · 2007-03-01

COMPLETED

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate CancerNCT00553878 · 2007-03-01

COMPLETED

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In MenNCT00363311 · 2006-07-01

COMPLETED

Metabolic Effects of Steroids in Obese MenNCT00983554 · 2005-06-01

UNKNOWN

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerNCT00375765 · 2005-04-01

COMPLETED

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskNCT00056407 · 2003-03-01

COMPLETED

Common conditions

Prostate Cancer11 Neoplasms, Prostate3 Benign Prostatic Hyperplasia2 Cancer1 Insulin Resistance1 Localized Prostate Cancer1 Obesity1

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

prostate cancer11 benign prostatic hyperplasia2 cancer1 obesity disorder1

Leading sponsors

GlaxoSmithKline 4 Canadian Urology Research Consortium 1 Endeavor Health 1 Kenneth Pienta, MD 1 Mary-Ellen Taplin, MD 1 Masonic Cancer Center, University of Minnesota 1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1 Pfizer 1 Sunnybrook Health Sciences Centre 1 University of Chicago 1 University of Colorado, Denver 1 University of Illinois at Chicago 1

Trial status mix

COMPLETED10

WITHDRAWN2

ACTIVE_NOT_RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

PHASE27

NA2

PHASE32

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.